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Serotonin (5-HT), norepinephrine (NE), and other neurotransmitters are modulated in
post-traumatic stress disorder (PTSD). In addition, pro-inflammatory cytokines (PIC) are
elevated during the progression of the disorder. Currently, the only approved pharmacologic
treatments for PTSD are the selective-serotonin reuptake inhibitors (SSRI) sertraline and
paroxetine, but their efficacy in treating PTSD is marginal at best. In combat-related
PTSD, SSRIs are of limited effectiveness. Thus, this study sought to analyze the effects
of the SSRI sertraline on inflammation and neurotransmitter modulation via a predator
exposure/psychosocial stress animal model of PTSD. We hypothesized that sertraline
would diminish inflammatory components and increase 5-HT but might also affect levels of
other neurotransmitters, particularly NE. PTSD-like effects were induced in male Sprague-
Dawley rats (n = 6/group × 4 groups). The rats were secured in Plexiglas cylinders and
placed in a cage with a cat for 1 h on days 1 and 11 of a 31-day stress regimen. PTSD rats
were also subjected to psychosocial stress via daily cage cohort changes. At the conclusion
of the stress regimen, treatment group animals were injected intraperitoneally (i.p.) with
sertraline HCl at 10 mg/kg for 7 consecutive days, while controls received i.p. vehicle.
The animals were subsequently sacrificed on day 8. Sertraline attenuated inflammatory
markers and normalized 5-HT levels in the central nervous system (CNS). In contrast,
sertraline produced elevations in NE in the CNS and systemic circulation of SSRI treated
PTSD and control groups. This increase in NE suggests SSRIs produce a heightened
noradrenergic response, which might elevate anxiety in a clinical setting.
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INTRODUCTION
Post-traumatic stress disorder (PTSD), an anxiety disorder
recently reclassified as a trauma- and stressor-related disorder,
can develop in response to real or perceived life-threatening
situations. According to the Diagnostic and Statistical Manual
of Mental Disorders 5 (DSM-5), a diagnosis of PTSD neces-
sitates exposure to a traumatic event, intrusive recollections,
avoidance of associated stimuli, negative cognitions/mood, hyper-
arousal, and a significant social impairment. All of these symp-
toms must persist for at least 30 days and not be due to
illness, medication, or substance abuse (American, 2013). To
date, no definitive diagnostic biomarkers have been identified
for PTSD. Recent research, however, points toward physiological
abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis,
sympathoadrenal medullary system, immune system, and neu-
rotransmitters that may be implicated in the disorder (Liberzon
et al., 1999; Söndergaard et al., 2004; Oosthuizen et al., 2005;
Wilson et al., 2013, 2014a). Although neurotransmitters are
modulated in PTSD development, it remains unclear whether
serotonin (5-HT) is the only neurotransmitter affected by
selective-serotonin reuptake inhibitors (SSRI). Changes in lev-
els of other neurotransmitters might explain why SSRIs have
met with such mixed results in PTSD therapy (Davidson et al.,
2001; Watts et al., 2013). To evaluate the effects of sertra-
line on neurotransmitter modulation, we employed a well-
documented predator exposure/psychosocial stress animal model
of PTSD demonstrating three hallmark features of the disor-
der: hormonal abnormalities, a long-lasting traumatic mem-
ory, and persistent anxiety (Zoladz et al., 2008, 2012). This
model also possesses both predictive and construct validity,
making it sensitive to clinically effective pharmacologic agents
while displaying similarities to human PTSD (Bourin et al.,
2007).
5-HT is a neurotransmitter responsible for many functions
in the central nervous system (CNS) and periphery. Seroton-
ergic cell bodies originate primarily in the raphe nuclei, but
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every area of the CNS receives 5-HT innervation (McGeer et al.,
1987). It influences aggression, arousal, sleep, anxiety, appetite,
fear, learning, and other processes (Dubovsky, 1994). 5-HT
is also the principle regulator of mood. A study by Peirson
et al. (Peirson and Heuchert, 2000) found lower platelet 5-HT2
receptor function was associated with depressed mood, while
Williams et al. (2006) demonstrated higher blood 5-HT levels
were correlated with better mood. An increased mood and overall
sense of well-being has been shown, in both psychiatric and
physical disorders, as protective and positively correlated with
resiliency behavior (Delamothe, 2005). Research has also demon-
strated that 5-HT-uptake sites in platelets were lower in PTSD
patients vs. controls (Arora et al., 1993). Lower 5-HT has also
been implicated in diminished physical health. Muldoon et al.
(2004) showed that a low prolactin response to fenfluramine, a
drug that increases 5-HT levels, was associated with metabolic
syndrome. Based on 5-HT’s action, it is reasonable to surmise
SSRIs should be effective in PTSD. The SSRIs sertraline and
paroxetine are the only Food and Drug Administration (FDA)
approved drugs for PTSD, but the modulation of other neuro-
transmitters in response to 5-HT reuptake has yet to be clearly
delineated.
Norepinephrine (NE) is a neurotransmitter involved in the
regulation of psychiatric and physical processes (Zoladz and
Diamond, 2013). In the brain, the locus coeruleus (LC) syn-
thesizes and releases NE, which modulates multiple functions
such as neuroplasticity, attention and memory, emotions, and
psychological stress (Benarroch, 2009). The LC also has projec-
tions to the spinal cord where NE is released from postgan-
glionic neurons in the sympathetic nervous system to initiate
the “fight-or-flight” response. In addition, chromaffin cells in
the adrenal medulla release NE and epinephrine into the blood-
stream, increasing heart rate and blood flow to skeletal muscles
and triggering the release of glucose. Persistent noradrener-
gic activity, however, has been linked with negative outcomes
in patients with congestive heart failure (CHF; Francis et al.,
1993) and diabetes (Ganguly et al., 1986). Studies have also
shown that individuals with PTSD have elevated cerebrospinal
fluid (CSF) levels of NE (Geracioti et al., 2001) and noradren-
ergic hyperresponsiveness to various stimuli (Liberzon et al.,
1999). Moreover, dysregulation of noradrenergic neurons has
been associated with hyperarousal and intrusive recollections
attributable to PTSD (Southwick et al., 1999). A study by Bracha
et al. (2005) noted irregularities in the number of cells of the
LC in postmortem examinations of combat veterans diagnosed
with PTSD. Thus, neurotransmitter modulation resulting in ele-
vated NE levels might increase sympathetic drive and elevate
anxiety.
Since the late 1980s, SSRIs have proven effective in the treat-
ment of depression (Doogan and Caillard, 1992; Miller et al.,
1998). In PTSD, however, SSRI efficacy can be classified as incon-
sistent at best (Friedman et al., 2007). A study by Davidson
et al. (2001) which was a part of the FDA approval process
for sertraline use in PTSD, demonstrated decreased severity of
symptoms and an overall increase in functioning in the PTSD
patients vs. controls. The results were achieved with multiple
investigator- and self-rated assessments. This study, however,
had uneven gender distribution (84% female), racial distribution
(83% white), and traumatic event distribution (64% physical or
sexual assault). The efficacy of sertraline in PTSD, therefore, may
be variable due to gender, demographics, and/or type of inci-
dent. The data showed a 45% increase in symptom improvement
in the treatment group, but also a 36% increase in symptom
improvement in the placebo group. Taken together, these num-
bers indicate that the majority of the noted improvement may
be due to a placebo effect. In addition, there were no physio-
logical measures conducted to analyze actual neurotransmitter
modulation during treatment. This information could be critical
in determining the true efficacy of SSRIs, as neurotransmitter
changes are not mutually exclusive events. With this in mind,
this study sought to analyze the modulation of neurotransmitters
and inflammatory components in the hippocampus, prefrontal
cortex (PFC), CSF, and plasma after a 7-day sertraline treatment
regimen.
MATERIALS AND METHODS
ETHICS STATEMENT
This study was carried out in accordance with the recommenda-
tions of the Institute for Laboratory Animal Research’s 2011 Guide
for the Care and Use of Laboratory Animals, under the auspices of
an animal care and use protocol approved by the Louisiana State
University Institutional Animal Care and Use Committee.
ANIMALS
Naïve adult male Sprague-Dawley rats (Harlan Laboratories, Indi-
anapolis, IN) were used in all experiments. The rats were the same
age (12 weeks) and approximately the same weight (±15 g) upon
delivery. Rats were pair-housed in standard plastic microisolator
cages with access to food and water ad libitum. The cages were
maintained in ventilated racks and randomly assigned to a rack
location to ensure groups were evenly distributed. The vivarium
room was kept on a 12-h light/dark cycle (0700–1900), temper-
ature was maintained at 20 ± 1◦C, and humidity ranged from
23–42%. After a 1-week acclimation period, the mean weight
of all rats was 308.5 g ± 2.5. Two cats, a male and a female
(Harlan Laboratories, Indianapolis, IN) were used for all predator
exposures. They were housed in an open room (15′ × 15′) in
the vivarium with access to food, water, and enrichment devices
ad libitum. The cat room was on the same light/dark cycle and
maintained at a similar temperature and humidity.
STRESS INDUCTION
The predator exposure/psychosocial stress regimen is designed to
induce a PTSD-like syndrome as true PTSD is clinically defined
as a human disorder. Following the acclimation period, rats were
weighed, ear-tagged, tail-marked, and 250–500 µL of blood was
drawn from the tail vein. The rats were then randomly assigned
to the PTSD or control group and returned to the vivarium for
24 h. The following day, PTSD rats were started on a predator
exposure/psychosocial stress regimen. Briefly, PTSD rats were
individually isolated in cylindrical, Plexiglas containers (IITC Life
Science, Inc., Woodland Hills, CA) and canned cat food was
smeared on the outside of the cylinders. The cylinders prevented
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direct contact with the cats, and the cat food induced move-
ment in the cats. Rats were then placed in a stainless steel cage
(76 cm × 76 cm × 60 cm) consisting of a solid metal floor with
a hinged, metal rod door, with a cat for one hour. The first cat
exposure was conducted during the light cycle (0700–1900). Ten
days later, a second cat exposure was conducted during the dark
cycle (1900–0700). In addition, the rats were subjected to psy-
chosocial stress by changing their cage cohort daily. The predator
exposure/psychosocial stress regimen continued for 31 days, after
which certain PTSD and control group rats were administered
sertraline intraperitoneally (i.p.) for 7 days. All groups were then
euthanized via CO2 inhalation, blood was collected by intracar-
diac puncture, exsanguination via perfusion was conducted with
a phosphate buffered solution, and the brains were removed. The
hippocampus and PFC were dissected and flash-frozen in liquid
nitrogen.
ELEVATED PLUS-MAZE (EPM)
Rats were randomly selected for either the control or the PTSD
group and were administered a baseline elevated plus-maze
(EPM) prior to the predator exposure. The EPM was also admin-
istered after the 31-day stress regimen and again after the 7-
day sertraline treatment. Rats were placed in the center of the
EPM (EB-Instruments (Bioseb), Tampa Bay, FL) facing an open
arm and allowed to roam freely for five minutes. Movement
was monitored via an overhead camera and captured with a
software program (BioEPM3C, EB-Instruments, Tampa Bay, FL).
The primary measurements were the total number of arm entries
and the time spent in the open vs. closed arms.
SERTRALINE
Rats were pair-housed and treatment group animals were injected
i.p. with sertraline HCl dissolved in 50% dimethyl sulfoxide
(DMSO) and dH2O at 10 mg/kg for 7 consecutive days (Maj and
Rogoz, 1999). Control rats were injected i.p. with vehicle.
REAL-TIME PCR ANALYSIS
Semi-quantitative real-time RT-PCR (n = 6/group) was used
to determine the mRNA levels of interleukin-1β (IL-1β),
interleukin-4 (IL-4), interleukin-10 (IL-10), and Toll-like
receptor-4 (TLR4) in the PFC and hippocampus. Total RNA
isolation, cDNA synthesis and RT-PCR were performed as
previously described (Agarwal et al., 2011). Gene expression was
measured by the ∆∆CT method and was normalized to GAPDH
mRNA levels. The data is presented as fold change of the gene of
interest relative to that of control animals.
WESTERN BLOT ANALYSIS
Tissue homogenates from the PFC and hippocampus were sub-
jected to Western Blot (WB) analysis (n = 6/group) for the
determination of protein levels of IL-1β, IL-4, IL-10, TLR4, and
β-Actin. The extraction of protein and WB was performed as
previously described (Agarwal et al., 2011). Primary antibodies
were commercially obtained: IL-1β, and β-Actin, 1:1000 dilution
(SC-7884 and SC-1616R respectively, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), TLR4, IL-4, and IL-10, 1:1000 dilution
(ab13556, ab9811, and ab9969 respectively, Abcam, Cambridge,
MA). Secondary antibodies were commercially obtained: anti-
rabbit, 1:5000 dilution (SC-2004, Santa Cruz Biotechnology,
Santa Cruz, CA).
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
Neurotransmitter concentrations were detected using Eicom
HTEC 500 HPLC system. The standard solutions of NE (MW
337.3), 5-HT (MW 212.68) and Isoproterenol (internal standard;
MW 247.7) were each 1 ng/µL concentrations. Sample prepa-
rations were carried out as previously described (Agarwal et al.,
2011; Wilson et al., 2014a).
HPLC detection of neurotransmitters
HPLC system working conditions: isocratic elution; mobile phase
(Citrate buffer in methanol with EDTA and sodium octane sul-
fonate); Eicompak SC-3ODS (ID 3.0 × 100 mm) column; flow
rate 340 µl/min; graphite working electrode WE-3G (Gasket GS-
25), (+750 mV vs. Ag/AgCl electrode); temperature 25◦C.
HPLC mobile phase
Citric acid monohydrate (8.84 g; MW 210.14), and 3.10 g of
sodium acetate (MW 82.03) in 800 ml of MilliQ Ultrapure fresh
water (>18.2 MΩ/cm) and 200 ml of HPLC grade methanol were
added. EDTA (MW 372.24; 0.005 g) and sodium octane sulfonate
(0.220 g), both from Dojindo Laboratories, Rockville, MD, were
added.
ELISA ANALYSIS
An ELISA kit was used to measure NE (MBS881383,
MyBioSource, San Diego, CA) levels in the CSF and plasma
according to manufacturer’s instructions.
STATISTICAL ANALYSIS
Data are presented as mean± SEM. Statistical analysis conducted
by one-way ANOVA with a Bonferroni post hoc test for multiple
comparisons, unpaired Student’s T-tests for two-column analy-
ses, and four-parameter logistic regression for curve fit. p-values
less than 0.05 were considered significant. Statistical analyses were
performed using Prism (GraphPad Software, Inc, La Jolla, CA;
version 5.0).
RESULTS
ELEVATED PLUS-MAZE PERFORMANCE
Prior to the start of the stress regimen, there were no differences
noted in baseline open arm exploration (Figure 1A) or total arm
entries (Figure 1B). After the 31-day stress regimen, the PTSD
group spent considerably less time in the open vs. closed arms as
compared to the control group, t(22) = 5.10, p < 0.0001, and as
compared to baseline, t(22) = 3.86, p< 0.001 (Figure 1A). Overall
ambulations, however, were not affected, F(3,44) = 0.974, p > 0.05
(Figure 1B). After the 7-day sertraline treatment, the PTSD +
Sert group displayed no increased open arm exploration vs. the
PTSD + Veh group, t(10) = 0.49, p > 0.05, or the control + Sert
group, t(10) = 4.59, p < 0.001. The control group also showed no
difference between the control + Sert and control + Veh groups,
t(10) = 0.43, p > 0.05, (Figure 2A). No differences were found in
overall ambulations between or within groups after the sertraline
treatment, F(3,20) = 0.55, p > 0.05 (Figure 2B).
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2014 | Volume 8 | Article 256 | 3
Wilson et al. Sertraline’s differential effects in PTSD
FIGURE 1 | Elevated plus-maze performance: within group
measurements. The PTSD group spent considerably less time in the open
vs. closed arms compared to the control group and to baseline (A). There
were no differences noted in overall ambulations between or within groups
(B). All data are presented as mean ± SEM. *p < 0.05 relative to the control
group. #p < 0.05 relative to within group measurements (baseline).
FIGURE 2 | Elevated plus-maze performance: between group
measurements. After sertraline treatment, the PTSD + Sert group
demonstrated no measureable improvement vs. the control + Sert group,
and the PTSD + Veh group displayed persistent anxiety vs. the control +
Veh group (A). There were no differences in overall ambulations in any of
the four groups after the treatment period (B). All data are presented as
mean ± SEM. *p < 0.05 between the treatment groups. #p < 0.05
between the vehicle groups.
CSF AND PLASMA NE ANALYSIS
In the CSF, NE was elevated in the PTSD + Veh vs. the
control + Veh group, t(8) = 4.22, p < 0.01. Sertraline raised
NE levels in the control + Sert vs. the control + Veh group,
t(8) = 4.96, p < 0.02, and NE was further elevated in the
PTSD + Sert vs. the PTSD + Veh group, t(8) = 3.72, p < 0.01
(Figure 3A). In the plasma, NE was higher in the treatment
groups, but it did not reach significance in any comparisons
(Figure 3B).
INFLAMMATORY MARKERS
In the PFC and hippocampus, the PTSD group demonstrated
elevated mRNA levels of IL-1β, F(3,18) = 3.56, p < 0.05 and
F(3,20) = 3.53, p < 0.05 (Figures 4A,B) and TLR4, F(3,20) = 4.11,
p < 0.05 and F(3,20) = 1.44, p > 0.05 (Figures 4C,D). Conversely,
there were diminished levels of IL-4, F(3,20) = 0.99, p > 0.05 and
F(3,20) = 6.65, p < 0.05 (Figures 4E,F) and IL-10, F(3,20) = 9.57,
p < 0.05 and F(3,20) = 7.34, p < 0.05 (Figures 4G,H) in the
same regions. Sertraline administration normalized the elevated
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FIGURE 3 | CSF and plasma NE levels. In the CSF, NE was elevated in
the PTSD + Veh vs. the control + Veh group and in the control + Sert vs.
the control + Veh group. NE was further elevated in the PTSD + Sert vs.
the PTSD + Veh group (A). In the plasma, NE was higher in the treatment
groups, but it did not reach significance in any comparisons (B). All data
are presented as mean ± SEM. *p < 0.05 between the PTSD groups.
@p < 0.05 between the control groups. #p < 0.05 between the vehicle
groups.
pro-inflammatory cytokines (PIC) mRNA and up-regulated anti-
inflammatory cytokine (AIC) to levels similar to or higher than
the control + Veh group. The PTSD group also displayed elevated
protein levels in the PFC and hippocampus of IL-1β, F(3,4) =
53.04, p < 0.05 and F(3,4) = 22.15, p < 0.05 (Figures 5A,B)
and TLR4, F(3,4) = 25.78, p < 0.05 and F(3,4) = 43.14, p < 0.05
(Figures 5C,D). The levels of AIC protein were lower for IL-4,
F(3,4) = 25.59, p< 0.05 and F(3,4) = 27.01, p< 0.05 (Figures 5E,F)
and IL-10, F(3,4) = 13.16, p < 0.05 and F(3,4) = 134.10, p < 0.05
(Figures 5G,H). Sertraline administration also normalized the
aberrant protein to levels similar as the control + Veh group.
NEUROTRANSMITTER MODULATION
To investigate the influence of sertraline on neurotransmit-
ter modulation, we examined endogenous levels of biogenic
amines in the hippocampus and PFC of control and PTSD
animals using HPLC. In the PFC, the level of the tryptamine
5-HT (Figure 6A) was significantly lower in the PTSD + Veh
vs. the control + Veh group, t(10) = 6.64, p < 0.0001. Con-
versely, the level of the catecholamine NE (Figure 6B) was
significantly higher in the PTSD + Veh group, t(10) = 8.04,
p < 0.0001. Sertraline expectedly raised 5-HT levels in the
PTSD + Sert and control + Sert groups to levels higher
than the control + Veh group F(3,20) = 32.62, p < 0.0001
(Figure 6A), but it also elevated NE in the PTSD + Sert
and control + Sert groups to levels higher than the con-
trol + Veh group F(3,20) = 26.59, p < 0.0001 (Figure 6B). In
the hippocampus, 5-HT (Figure 6C) was significantly lower
in the PTSD + Veh vs. the control + Veh group, t(10) =
6.03, p < 0.0001, while NE (Figure 6D) was higher, t(10) =
8.94, p < 0.0001. Similar to results in the PFC, sertraline
normalized 5-HT to pre-stress levels, F(3,20) = 18.35, p < 0.0001
(Figure 6C), but it doubled NE in the control + Sert group
and more than tripled NE in the PTSD + Sert group com-
pared to the control + Veh group, F(3,20) = 124.10, p < 0.0001
(Figure 6D).
DISCUSSION
The present study sought to analyze neurotransmitter modulation
and pro- and AICs in the PFC, hippocampus, CSF, and plasma
of rats subjected to a PTSD model and subsequently treated with
sertraline. A myriad of animal models designed to create PTSD-
like effects are reported, but the model by Zoladz et al. (2008,
2012) has been shown to cause common symptoms reported in
humans with PTSD (Brewin et al., 2000; Nemeroff et al., 2006)
such as heightened anxiety, exaggerated startle response, impaired
cognition, and increased cardiovascular reactivity. Although ani-
mal models have certain well-understood limitations, a major
component missing from human PTSD research is the ability to
ascertain physiological data directly from specific brain regions
immediately after a stressful event. The majority of the human
physiological data gathered in vivo is derived from saliva, blood
and urine, which may not accurately reflect neurotransmitter
modulation in the brain and certainly cannot distinguish between
changes in specific brain regions. We have successfully obtained
such data with this Sprague-Dawley rat model, and to our
knowledge, we are the first to report the modulation of biogenic
amines and inflammatory components in response to sertraline
administration in the brains of PTSD animals. Three novel and
important findings emerged from this study. First, 5-HT sup-
pression in the brain regions examined was normalized with
sertraline, but NE levels also significantly increased in response
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FIGURE 4 | Pro- and Anti-Inflammatory Marker mRNA. In the PFC and
hippocampus, the PTSD group demonstrated elevated mRNA levels of IL-1β
(A and B) and TLR4 (C and D). Conversely, there were diminished levels of
IL-4 (E and F) and IL-10 (G and H) in the same regions. Sertraline
administration normalized the elevated PIC mRNA and up-regulated
anti-inflammatory cytokine (AIC) to levels similar to or higher than the
control + Veh group. All data are presented as mean ± SEM. *p < 0.05
between the PTSD groups. #p < 0.05 between the vehicle groups.
to the treatment. Second, sertraline produced anti-inflammatory
effects as evidenced by decreased PICs and elevated AICs. Lastly,
despite attenuating inflammatory markers, sertraline provided no
positive benefit in relation to anxiety or behavior.
The modulation of various neurotransmitters observed with
the predator exposure/psychosocial stress model is in concert
with many of the neurotransmitter changes seen in human
PTSD patients (Yehuda et al., 1992; Arora et al., 1993; Geracioti
et al., 2001, 2013). Previous research has shown that stress
blocks long-term potentiation (LTP) in the hippocampus as well
as impairs hippocampal function (Kim and Diamond, 2002;
Diamond et al., 2007). The hippocampus, the primary region
for spatial and long-term memory storage, expresses all of the
5-HT receptor families and reflects overall serotonergic functions
relating to cognition and mood in this region (Berumen et al.,
2012). During stress, glucocorticoid production can reduce the
excitability of hippocampal neurons, and 5-HT may have a pro-
tective effect against such damage by activating 5-HT1A receptors
(Joca et al., 2007). Persistent activation of the HPA axis and
excessive production of glucocorticoids, however, may directly
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FIGURE 5 | Pro- and Anti-Inflammatory Marker Protein. The PFC and
hippocampus demonstrated elevated protein levels of IL-1β (A and B)
and TLR4 (C and D) in the PTSD group. Conversely, the levels of AIC
protein in these regions were lower for IL-4 (E and F) and IL-10 (G and
H). Sertraline administration also normalized the aberrant protein to levels
similar as the control + Veh group. All data are presented as mean ±
SEM. *p < 0.05 between the PTSD groups. #p < 0.05 between the
vehicle groups.
reduce hippocampal 5-HT levels and adversely affect normal
serotonergic transmission, thus contributing to heightened fear,
depressed mood, and reduced resilience. The hippocampus also
contains multiple NE receptors which, when activated during
stress, may contribute to the reinforcement of long-term mem-
ories (Jurgens et al., 2005). In a study by Geracioti et al. involving
male combat veterans with PTSD, CSF concentrations of NE
were significantly higher vs. controls (Geracioti et al., 2001).
This finding could possibly explain why memories formed during
extremely stressful events persist over time. Other evidence of
catecholamine dysregulation in PTSD includes elevated urine
catecholamine excretion, exaggerated biochemical responses to
yohimbe, and clinical efficacy of adrenergic blockers (Southwick
et al., 1999).
The PFC is responsible for executive functions such as con-
sequences, drive, and social “control”. It is highly innervated by
serotonergic neurons from the raphe nuclei, and it expresses
an abundance of 5-HT receptors. The serotonergic neurons
and 5-HT receptors, specifically the 5-HT1A and 5-HT2A recep-
tors, are key modulators of the PFC-amygdala-corticolimbic
circuit involved in threat and emotional responses (Fisher
et al., 2011). PTSD-related aberrancies in this serotonergic
system may cause inappropriate or incomplete extinction of
conditioned fear. The PFC also contains NE receptors and
receives input from NE neurons from the LC, which are acti-
vated during the stress response (Finlay et al., 1995). Pathog-
ical or stress-related elevations of NE in the PFC, however,
may inhibit working memory and performance (Zhang et al.,
2013). Current neuroimaging research indicates that the PFC
is hyporesponsive during symptomatic PTSD states and that
this responsiveness is inversely proportional to symptom sever-
ity (Shin et al., 2006). Whether marked elevations in NE
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2014 | Volume 8 | Article 256 | 7
Wilson et al. Sertraline’s differential effects in PTSD
FIGURE 6 | 5-HT and NE Modulation. In the PFC, the level of 5-HT (A)
was significantly lower in the PTSD + Veh vs. the control + Veh group.
Conversely, the level of NE (B) was significantly higher in the PTSD +
Veh group. Sertraline expectedly raised 5-HT levels in the PTSD + Sert
and control + Sert groups to levels higher than the control + Veh group
(A), but it also elevated NE in the PTSD + Sert and control + Sert groups
to levels higher than the control + Veh group (B). In the hippocampus,
5-HT (C) was significantly lower in the PTSD + Veh vs. the control + Veh
group, while NE (D) was higher. Similar to results in the PFC, sertraline
normalized 5-HT to pre-stress levels, but it doubled NE in the control +
Sert group and more than tripled NE in the PTSD + Sert group compared
to the control + Veh group (D). All data are presented as mean ± SEM.
*p < 0.05 between the PTSD groups. #p < 0.05 between the vehicle
groups.
directly or indirectly diminish PFC responsiveness and sub-
sequent performance on cognitive emotional tasks remains
unclear.
The role of inflammation in pathological conditions such
as cardiovascular disease, diabetes mellitus, metabolic syn-
drome, and neurological disease is well established (Pall and
Satterlee, 2001; Elks and Francis, 2010; Agarwal et al., 2011;
Alexopoulos et al., 2013). We recently demonstrated oxidative
stress and inflammation were up-regulated in the brain and
systemic circulation of rats subjected to the predator expo-
sure model (Wilson et al., 2013). In chronic stress-related con-
ditions such as PTSD, a sustained sympathoexcitatory state
can alter the TH1/TH2 cell balance and increase PIC produc-
tion (Chrousos, 2000). Research presents strong evidence that
cytokines and inflammation may be directly linked to psy-
chiatric disorders, but whether they are causal or nonspecific
immunological side-effects remains unresolved (Schiepers et al.,
2005). Inflammatory cytokine levels have been shown to be
inversely proportional to 5-HT levels, and it is hypothesized
that PICs can diminish tryptophan by activating the tryptophan-
metabolizing enzyme indoleamine-2,3-dioxygenase (IDO; Heyes
et al., 1992). There is also evidence that PICs counteract the
negative feedback of glucocorticoids on the HPA axis, altering
its function (Miller et al., 1999). In our previous work, we
found that valproic acid (VA) attenuated inflammation, but it
differed from sertraline in that it did not result in noradren-
ergic hyperresponsiveness and actually modulated NE to levels
similar to untreated controls. In addition, VA lowered anxi-
ety and resulted in vast improvements on the EPM (Wilson
et al., 2014b). The fact that both of these compounds decreased
inflammatory components but did not equally improve EPM
performance indicates inflammation and oxidative stress may be
contributors, but not the sole causal factors in terms of PTSD
pathophysiology.
We have demonstrated that sertraline increases 5-HT and
NE, and that it attenuates inflammation in the hippocampus,
PFC, and CSF. Based on these mechanisms, its administra-
tion should result in decreased anxiety and improved resilience.
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In our experiments, however, we observed no improvement
on the EPM that indicated reduced anxiety in the rats. The
EPM is widely used as a measure to test fear or anxiety and
has been extensively validated for use in rats (Pellow et al.,
1985; Korte and De Boer, 2003). Anxiogenic compounds or
procedures can increase avoidance of the fear-provoking open
arms, whereas anxiolytic compounds or procedures can increase
open arm exploration (Pellow et al., 1985). It should be noted,
however, that not all anxiolytic compounds modify behav-
ior in PTSD. Zoladz et al. (2013) demonstrated the ineffec-
tiveness of clonidine and amitriptyline, but showed a marked
improvement in behavior with tianeptine. The anxiolytic effects
of increased 5-HT and attenuated inflammation should have
resulted in increased open arm exploration compared to the
PTSD + Veh group. The fact that no significant changes were
noted between the treated and untreated PTSD groups suggests
other mechanisms might be acting as endogenous anxiogenic
agents. One such mechanism might be elevated CNS NE and
increased sympathetic tone. Noradrenergic hyperresponsiveness
has previously been shown to contribute to PTSD pathophysi-
ology (Southwick et al., 1993). It has also been suggested that
the LC neurons, responsible for CNS NE production, con-
stitute the first or second step of the PTSD circuit (Bracha
et al., 2005). Our findings of elevated NE in the hippocam-
pus, PFC, and CSF despite sertraline administration provide
sound evidence that exaggerated sympathoexcitation may be
a primary reason underlying the modest efficacy of SSRIs in
PTSD.
CONCLUSIONS
We utilized a predator exposure/psychosocial stress animal model
of PTSD to analyze the effects of sertraline on neurotransmitter
modulation and inflammation in the rat hippocampus, PFC,
CSF, and plasma. We found that sertraline increased 5-HT and
NE levels in the hippocampus, PFC, and CSF. We also discov-
ered that sertraline attenuated inflammation by lowering PICs
and elevating AICs. Despite these seemingly beneficial changes,
however, anxiety did not diminish in the PTSD + Sert vs. the
PTSD + Veh groups. We propose that noradrenergic hyperre-
sponsiveness, evident by exaggerated levels of NE present in
the hippocampus, PFC, and CSF, might be a primary factor in
persistent anxiety and a major reason that SSRIs have demon-
strated poor efficacy in PTSD. To our knowledge, this is the
first study to provide a molecular rationale for this unsatisfac-
tory record of accomplishment. This insight might allow for
more targeted pharmacologic therapies with an emphasis on
inflammatory suppression and control of sympathetic drive. It
would be an oversimplification, nonetheless, to presume that a
persistent noradrenergic tone is the sole causal factor in PTSD
development. The autonomic nervous system (ANS), endocrine
system, and immune system are indelibly linked with CNS dis-
orders and identifying one system as the cause of PTSD might
be impossible. Overall, our results demonstrate that there are
CNS-specific modifications in neurotransmitters, immunomod-
ulators, and ANS activity in response to sertraline in the predator
exposure/psychosocial stress model. Further research is critical to
delineate, if possible, which of these systems actually contributes
to PTSD pathophysiology and which are producing nonspe-
cific responses common to multiple psychiatric etiologies. In
addition, direct comparisons with SSRIs and other compounds
demonstrating effectiveness in PTSD such as VA and tianeptine
are warranted.
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